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Background: The development of complex responses to hypoxia has played a key role in the evolution of
mammals, as inadequate response to this condition is frequently associated with cardiovascular diseases,
developmental disorders, and cancers. Though numerous studies have used mice and rats in order to explore
mechanisms that contribute to hypoxia tolerance, these studies are limited due to the high sensitivity of most
rodents to severe hypoxia. The blind subterranean mole rat Spalax is a hypoxia tolerant rodent, which exhibits
unique longevity and therefore has invaluable potential in hypoxia and cancer research.
Results: Using microarrays, transcript abundance was measured in brain and muscle tissues from Spalax and rat
individuals exposed to acute and chronic hypoxia for varying durations. We found that Spalax global gene
expression response to hypoxia differs from that of rat and is characterized by the activation of functional groups of
genes that have not been strongly associated with the response to hypoxia in hypoxia sensitive mammals. Using
functional enrichment analysis of Spalax hypoxia induced genes we found highly significant overrepresentation of
groups of genes involved in anti apoptosis, cancer, embryonic/sexual development, epidermal growth factor
receptor binding, coordinated suppression and activation of distinct groups of transcription factors and membrane
receptors, in addition to angiogenic related processes. We also detected hypoxia induced increases of different
critical Spalax hub gene transcripts, including antiangiogenic genes associated with cancer tolerance in Down
syndrome human individuals.
Conclusions: This is the most comprehensive study of Spalax large scale gene expression response to hypoxia to
date, and the first to use custom Spalax microarrays. Our work presents novel patterns that may underlie
mechanisms with critical importance to the evolution of hypoxia tolerance, with special relevance to
medical research.
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The mole rat, Spalax ehrenbergi superspecies, is a wild
subterranean rodent which lives in underground habi-
tats, characterized by extreme hypoxic/hypercapnic con-
ditions, and darkness [1]. Various chromosomal species
of Spalax were identified, with diploid numbers ranging
from 2n = 52 to 2n = 60. Phylogenetically, Spalax was
suggested to belong to the Muroidea superfamily, and is
closely related to Murine species (e.g., mice, rats). A* Correspondence: markband@illinois.edu
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reproduction in any medium, provided the orSpalax-Murine common ancestor was suggested to live
approximately 39 million years ago [2], during which
Spalax acquired unique biological mechanisms to cope
with environmental hypoxia, darkness, and other under-
ground related stresses. Unlike various hibernating and
diving mammals which experience short episodes of
internal/environmental hypoxia, Spalax lives under
chronic environmental hypoxia [3]. During the rainy sea-
son, the oxygen level in Spalax underground habitats
was detected at 6% with CO2 levels around 7% [4]. In
the laboratory, Spalax survives at 3% O2 for up to 14
hours, as compared to less than 4 hours for rats [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mouse, it differs in many aspects of metabolism, genet-
ics, epigenetics, physiology and behavior. This species is,
in most aspects, blind, with an impaired hearing at high
frequency, like other subterranean species [5]. Compared
with aboveground rodent species, Spalax has a higher
density of blood vessels in muscle tissues, an increased
lung diffusion capacity, and a higher erythrocyte count
[6,7]. Spalax resting heart rate is about 40% of the
expected rates for animals of similar size, reflecting
increased aerobic capacity especially during tunnel sys-
tem construction under hypoxic conditions [8]. Several
hypoxia induced hub genes were found to exhibit unique
expression patterns in Spalax, including Hypoxia indu-
cible factor1-alpha (HIF1a), erythropoietin (Epo), and
Epo receptors [9,10].
Spalax adults weigh 100–150 g, and can live at least
20 years in captivity. To the best of our knowledge,
tumors have never been observed in Spalax wild or cap-
tive individuals, as compared to laboratory mice that tend
to develop age related cancer. Similarly, another subterra-
nean hypoxia resistant rodent, the naked mole rat, is con-
sidered to be cancer resistant and to exhibit unique
longevity [11-13]. It was previously suggested that mo-
lecular pathways associated with hypoxia tolerance share
common anti-apoptotic functions with those associated
with tumor adaptivity [14-16]. Similarly, expression pat-
terns of Spalax vascular endothelial growth factor (Vegf )
are similar to those of tumors Vegf [6,17]. More generally,
the association between hypoxia related and cancer related
responses is based on wide evidence that tumor invasive-
ness requires cellular adaptation to hypoxic microenviron-
ments [18]. Unlike the Spalax cellular response, hypoxic
cancer cells acquire genomic instability [19].
We have used high throughput expression profiling to
elucidate the response to hypoxic stress in Spalax. In an
early study, a cross species microarray hybridization
method was used for the detection of hypoxia induced
expression patterns unique to Spalax [20]. More re-
cently 454 technology was applied to sequence and as-
semble the Spalax galili transcriptome, using brain and
muscle cDNA libraries created from pools of RNA
extracted from individuals exposed to normoxia and
hypoxia [21]. A total of about 50,000 Spalax contigs
were assembled and mapped to more than 12,000 hom-
ologous mouse genes. 454 read count data was used for
the detection of putative hypoxia induced Spalax genes.
In the present study, we utilized the newly sequenced
Spalax genes [21] for the design of a custom Spalax
microarray. Gene expression was measured in Spalax
brain and muscle tissues from individuals exposed to dif-
ferent levels and time courses of hypoxia. More than
2,000 genes were found to be regulated during hypoxia
in at least one tissue/treatment. We found a battery ofbiological processes/ontologies with significant over/
under representation among hypoxia induced genes in
Spalax. Here we report on the underlying biological pro-
cesses and specific genes under regulation in hypoxic
environments and potential hypoxia induced differences
in expression patterns between Spalax and an above
ground mammal, the rat.
Methods
Ethics statement
All animal handling protocols were approved by the
Haifa University Committee for Ethics on Animal Sub-
ject Research, permit # 193/10 and approved by the
Israel Ministry of Health. Permit # 193/10 covers all pro-
tocols and experimentation involving Spalax, rats or
mice used in this experiment. This is a renewable permit
which is current from July 2010– July 2014. The permit
covers the number of animal subjects, housing condi-
tions, veterinary regulations and inspections, hypoxia
treatments and sacrifice methods for this experiment.
No permits for capturing Spalax in unprotected areas
are required. (Israel Nature Reserves Authority).
Animals
Spalax were captured in the field and housed under am-
bient conditions in individual cages in the animal house
of the Institute of Evolution. Animals were placed in a
70x70x50 cm chamber divided into separate cells where
the chosen gas mixture was delivered at 3.5 l/min.
Experiments were performed on adult animals of similar
weight (100-150g) and included both genders. Three
hypoxic conditions were chosen for Spalax: acute hyp-
oxia of 3% O2 (4 animals), the lower limit of survival as
determined in the lab, 6% O2 (3 animals), the level of
oxygen measured in the field within Spalax tunnels after
heavy rainfall [4] and mild long term hypoxia of 10% O2
for up to 44 h (5 animals), which is the estimated condi-
tion and time experienced by Spalax during tunnel re-
construction, as well as normoxia, 21% O2 (4 animals).
Rats were exposed to either normoxic (21% O2) or hyp-
oxic (6% O2) conditions (3 animals each condition).
Tissues
Animals were sacrificed by injection with Ketaset CIII
(Fort Dodge, USA) at 5 mg/kg of body weight. Tissues
were removed and immediately frozen in liquid nitrogen.
Brain tissues taken from individuals exposed to 3%, 6%,
10% and 21% O2, will be denoted br3, br6, br10 and br21,
respectively. The corresponding hypoxic conditions for
muscle tissues will be denoted mu3, mu6, mu10, mu21.
RNA and cDNA preparation
Total RNA was extracted from whole brain or trapezius
muscle tissues using TRI Reagent (Molecular Research
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turer’s instructions. RNA samples were treated with
DNase I (Life Technologies, Grand Island, NY). All sam-
ples were tested for quality using an RNA nanochip on
the Bioanalyzer (Agilent Technologies, Santa Clara, CA).
2 μg of total RNA were used for first strand cDNA using
M-MuLV-H- reverse transcriptase (New England Bio-
labs, Ipswich, MA). The cDNA equivalent of 0.5 ng
RNA was used in each real-time PCR reaction.
Quantitative PCR mRNA quantification
mRNA expression levels were measured using real-time
quantitative PCR (RLT-q-PCR). mRNA quantification
was performed with three technical replicates (wells) for
each sample using an ABI 7900 HT (Life Technologies)
sequence detector in 384 well format. Gene expression
was normalized to 18s rRNA. Primers were designed
using Primer Express 2 software (Life Technologies)
against Spalax transcripts. The primer sequences used for
RLT-q-PCR are shown in Additional file 1: Table S1.
Slopes of standard curves were: DSCR1: -3.2; TSP1: -3.22;
TNNC2: -3.2; TNNT3: -3.19; TNNI2: -3.2; 18S: -3.28. R2
was > 0.99 for all curves. All primer sets gave a single peak
in the dissociation curves. Fold changes and significance
levels were computed using REST software [22]. Signifi-
cance was determined by permutation test using 10,000
iterations. Quantitative PCR was carried out on the same
samples used for microarray analysis with the addition of
2 Spalax normoxic and 3 Spalax hypoxic 10% O2 brain
samples available from previous experiments.
Microarray probe design
Custom microarray probes were designed using contig
sequences from the Spalax galili muscle and brain tran-
scriptome assembly. In these datasets, contigs are anno-
tated based on their predicted homology to mouse, rat,
and human genes. Contigs/reverse complement contigs
were aligned to homologous mouse Ensembl / Gene
Bank transcripts, and probes were designed as close as
possible to the 3’ end. In order to select the probes with
the highest reliability, probes mapped to Spalax mouse
conserved regions, and to large contigs were selected.
Microarray labeling and hybridization
For each sample 200 ng of total RNA was labeled using
the Agilent 2-color Low Input Quickamp Labeling kit
(Agilent Technologys, Santa Clara, CA) according to the
manufacturer's protocols. Labeled samples were hybri-
dized to a custom designed Spalax 8 x 15K earray and
scanned on an Axon 4000B microarray scanner (Mo-
lecular Devices, Sunnyvale, CA) at 5 um resolution. All
microarray data files were submitted to Gene Ontology
Omnibus (GEO) and are available for download
with accession numbers: Platform, GPL15478; Spalaxsamples: GSM921638, GSM921946, GSM921979,
GSM922315, GSM922635, GSM922638, GSM922639,
GSM922640, GSM922799, GSM922977, GSM922978,
GSM922979, GSM923030, GSM923039, GSM923051,
GSM923052; Rat samples: GSM950599, GSM950600,
GSM950716, GSM950717, GSM950718, GSM950719,
GSM950770, GSM950865, GSM950940, GSM950947,
GSM951034, GSM951035; Series GSE37619.
Differential expression analysis
Spotfinding was carried out using GenePix 6.1 software
(Molecular Devices, Sunnyvale, CA). Single channel dif-
ferential expression analyses were conducted using
Limma 3.10 [23], as follows: Background correction of
signal intensities was carried out on GenePix data.
Within array normalization, Loess, was performed on
the background corrected signals, followed by quantile
normalization between arrays. Limma separate channel
analysis was conducted, and P-values adjusted for mul-
tiple testing were calculated by using the Benjamini and
Hochberg method [24].
Enrichment analysis
Three input lists were prepared: (1) a list of genes upre-
gulated under the tested tissue/condition; (2) a list of
downregulated genes; (3) a background list that includes
all genes represented in the array. Before analysis, genes
represented by probes with very low Cy5 and Cy3 emis-
sion intensities (<50) were removed from the three input
lists. The IDs of mouse Ensembl genes mapped to Spa-
lax contigs were used as an input. Gene Ontology (GO)
enrichment analysis was conducted by comparing lists of
hypoxia up/downregulated genes against the background
list, using DAVID [25]. Similarly, the same procedure
was repeated after removing entries linked to Spalax
contigs mapped ambiguously to multiple genes. Associ-
ation between enriched terms was calculated based on
the size of overlap between sets of genes belonging to
different terms, and visualized using Cytoscape [26].
Heat Map generation
Heat map representation of differentially expressed
genes was carried out with the R package Neatmap [27]
using the average linkage algorithm.
Results
Estimating the scale of hypoxia induced differential
expression in Spalax
Based on multiple probe sequences designed from the
Spalax brain/muscle transcriptome assembly we created a
custom Spalax microarray using Agilent earray technology.
S. galili muscle and brain transcript levels were measured
in four experiments, under the following conditions: (1) 3%
O2 for 6 hrs (2) 6% O2 for 6 hrs (3) 10% O2 for 44hrs (4)
Figure 1 Venn diagram of treatment specific hypoxia induced
gene groups in Spalax. Brain/muscle differential expression at 3%
6 hrs, 6% 6 hrs, 10% 44 hrs hypoxia, are denoted br3/mu3, br6/mu6,
br10/mu10, respectively. Numbers inside closed regions represent
counts of genes which are found to be differentially expressed as
compared to normoxia. The numbers beside each diagram
represent the union of the sets of differentially expressed genes.
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response to extreme environmental hypoxia. This is the
lowest oxygen concentration tested under laboratory con-
ditions and is lethal to Spalax after >14 hours. Experiment
2 (6% O2 6 hrs) aimed at detecting responses similar to
those elicited under acute environmental hypoxia as mea-
sured in Spalax underground habitats after rainfall. Ex-
periment 3 (10% O2 44 hrs) tested responses under mild
chronic environmental hypoxia. Under these conditions
Spalax can conduct strenuous, energy consuming, tunnel-
ing work in its natural habitats. Differentially expressed
genes were detected using Limma single channel analysis
(Benjamini and Hochberg adjusted P-value <0.05) by com-
paring hypoxic to normoxic expression levels in brain and
muscle (i.e., 3% vs. 21%, 6% vs. 21%, 10% vs. 21%). Limma
differential expression statistics for all genes are shown in
Additional file 2: Table S2. Responses to acute extreme
hypoxia (i.e., mu3/6, br3/6) are profoundly different than
responses to mild chronic hypoxia (i.e., mu10, br10) in
terms of the number of genes affected in both types of
responses (Figures 1, 2).
Core responses to hypoxia in Spalax brain and muscle
As Figures 1 and 2 demonstrate, multiple genes exhibit
similar response to hypoxia in both Spalax muscle and
brain, and in both 3% and 6% hypoxia. These results
may indicate that similar processes are activated under
different conditions of hypoxia in Spalax. We further
tested which types of processes are specifically asso-
ciated with groups of genes expressed in more than one
tissue/treatment. Accordingly, we selected groups of
Spalax genes up/down regulated under hypoxia in ≥1,
≥2, and ≥3, out of six experiments (i.e., mu3/6/10,
br3/6/10), as test groups. The test groups were compared
to a background group composed of all genes represented
on the array. Multiple processes were detected with highly
significant enrichment among hypoxia responsive genes
Additional file 3: Table S3. We assessed the biological simi-
larity between enriched terms and it appears that many
terms represent related processes. Accordingly, Figure 3
shows network representation of the biological association
between terms enriched at adj. p-value < 0.05, among
genes upregulated in at least 3 experiments. For example,
as the figure indicates, terms representing different extra-
cellular and transmembrane domains are associated with
each other, as well as those representing cellular migration
functions, growth factor binding, non-canonical EGF re-
ceptor (EGFR) ligands, and angiogenesis.
We further tested responses activated under extreme
hypoxia in both muscle and brain. As a test group we
selected all Spalax genes that were differentially expressed
in both brain and muscle (adj. p-value <0.05) under 3%
hypoxia for 6 hrs (br3\mu3 gene set). Of the 120/92
genes that were up/downregulated, 75/28 genes wereassociated with at least one significantly enriched Gene
Ontology term (adj. p-value <0.05) (Figure 4, Additional
file 4: Table S4). Collectively, these results indicate very
strong enrichment of multiple groups of terms, including
some exceptional terms such as ‘negative regulation of
apoptosis/cell death’ and ‘basic-leucine zipper (bZIP) tran-
scription factors’ (TFs). Table 1 summarizes the lists of
genes associated with core hypoxia ontologies.
Processes suppressed during hypoxia in Spalax
In order to detect processes that may be suppressed under
hypoxia, groups of genes downregulated in hypoxia were
compared to all genes tested in the array. Groups of TFs,
including zinc fingers and C2H2-like zinc fingers, are sig-
nificantly overrepresented among genes downregulated in
mu3, mu6, br3, and br3\mu3 (Figure 5, Additional file 3:
Figure 2 Heat map representation of differentially expressed genes. Based on microarray intensities, we performed hierarchical clustering of
hypoxia induced genes and samples. The results indicate sharp differences between acute and chronic responses in Spalax, with clear tissue and
treatment specific clades. In addition, it appears that acute hypoxia (3% and 6% O2) elicits similar responses both within and between tissues.
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Table S5). In addition, the Krüppel associated box (KRAB)
subgroup of C2H2 Zinc finger TFs is overrepresented
among genes downregulated in mu3, br3, and br3\mu3.
These results indicate that the repression of zinc finger TF
groups is accompanied by the upregulation of several
other TF groups under acute extreme hypoxia. Though
these TF groups include multiple paralogs, where many
probes mapped ambiguously to the mouse genome,
similar results are also found after excluding such cases
(Additional file 3: Tables S3, Additional file 4: Table S4,
Additional file 6: Table S6). Collectively, hundreds of TFs
are found to be enriched among genes suppressed under
hypoxia. In addition, genes encoding mitochondrial pro-
teins, and/or include transit peptide domains, are signifi-
cantly overrepresented among downregulated genes in
mu10 (see Figure 5). In most experiments, test groups
composed of genes identified to be down regulated with
adjusted P-value < 0.25, show highly significantenrichment of mitochondrial genes (e.g. enrichment
adjusted P-value < 10-24 in mu10), as well as genes encod-
ing electron transport chain proteins, oxidation/reduction
proteins, and proteins located in the inner mitochondrial
membrane (results not shown). Though the use of this lib-
eral P-level for the test group selection might lead to non-
negligible false positive detection, when sets of randomly
selected genes of the same size were taken as test groups,
no significant terms were found. Accordingly, the forgoing
enrichment of downregulated mitochondrial genes should
be noted, however additional bioinformatic tests will be
needed for validations.
Response to acute hypoxia in Spalax
A total of 258, 360, 216, and 129 genes were mapped to
significantly enriched functional terms among 567, 653,
367, and 201 genes significantly upregulated in mu3, mu6,
br3 and br6 respectively (Figures 6 and 7, Tables S5 and



























































































Figure 3 Clusters of significantly enriched functional groups among genes upregulated under hypoxia in at least 3 experiments. Nodes
(circles) represent enriched gene ontology terms. Node size corresponds to the number of genes mapped to the term. Different pairs of terms
(i.e., nodes) are connected by edges, where increased edge thickness corresponds to larger pairwise similarity, reflecting the proportion of shared
genes.
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than one experiment. These include terms that are angio-
genesis related (in br3, br6, br10, mu3), disulfide bonds,
glycoproteins, and signal peptides (in br3, br6, br10, mu3,
mu6), bZIP TFs and regulation of transcription (in br3,
br6), extracellular matrix binding and adhesion related (in
br10, mu6, mu10), immune response related (in br6, br10,
mu3), regulation of apoptosis related (in br3, mu10), and
transmembrane proteins (in br3, br10, mu3, mu6), among
many others. In addition, different groups of terms are
found to be experiment specific, such as the mu6 specificterm ‘cytoplasmic vesicles’ and its descendent term ‘mela-
nosome’ (Figure 7). While melanosomes are not formed in
muscle, many genes expressed in melanosomes have
powerful antioxidant functions [28]. These results possibly
reflect an overlap between gene sets involved in protective
pathways induced by UV stress with those induced by pro-
duction of radical oxygen species in hypoxic muscle.
Responses to chronic hypoxia
Terms found to be significantly enriched in mu10 include:


































blood-vessel / vasculature development
transcription regulation *SP
TSP1 (Thrombospondin, type 1 repeat)
protein dimerization activity
in utero embryonic development
regulation of cell proliferation





vascular endothelial growth factor receptor activity
regulation of transcription *GO




mu3 br3 adj. P-value
mu3 br3  gene count 
Figure 4 Functional groups significantly enriched among genes upregulated in both Spalax muscle and brain after 3% 6hrs hypoxia
(mu3\br3). Red line chart represents Benjamini adjusted P-values for specific ontology categories. Blue bars denote gene counts. A total of
75 genes are associated with at least one significant group. Enrichment of the same term may be detected using different databases (e.g. GO,
Swiss-prot keywords, InterPro, Smart, KEGG).
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tion of cell adhesion’, ‘reproductive process’, and others
(Figure 7). Collectively, these terms correspond to pro-
cesses that contribute to cell survival under an internal
state of hypoxia (e.g., in tumor microenvironments). Yet,
it should be noted that with the exception of cancer related
terms, most of the other terms in mu10 did not remain
significant after removing genes with ambiguous annota-
tions, though many had adj. p-value <0.1 (Additional file 6:
Table S6).
Very strong enrichment patterns were detected in
br10 (Figure 8). In addition to core terms enriched in
most other conditions, several terms appear exclu-
sively in br10, including different immune response
related terms, glycolysis, and ’contractile tissue’
related terms. As many of these genes are not typic-
ally regulated in brain tissues we verified thisresponse using quantitative PCR with additional
samples.
Comparing Spalax and rat expression under 6% O2
Using a rat specific microarray, gene expression was
measured in brain and muscle tissues from rat indivi-
duals exposed to 6% O2 for 6 hrs. The same basic micro-
array procedures were used in both species (see
Methods). We did not expose rats to lower oxygen levels
as such exposure becomes lethal within 2–4 hours. Simi-
lar to Spalax, angiogenesis and adhesion related terms
are enriched among hypoxia induced genes, though the
total number of responsive genes was found to be lower
than Spalax (132/35 up/down regulated in rat br6, and
219/139 up/down regulated in rat mu6). We identified
hundreds of genes that respond to hypoxia in only one
of the two species (adj. p-values <0.05 vs. >0.5), among






S1pr1 2 Icam1 2 Fntb 3 Gna13 2
Plaur 2 Serpine1 2 Btg1 4 Pecam1 6
Nrip1 2 Tlr4 2 Loc100046643 4 Ppara 3
Acvrl1 5 Acvrl1 5 Fzd4 2 C3ar1 2 Zbtb16 5 Serping1 2
Col18a1 3 Ltbp1 2 Arntl 2 Serpina5 4 Positive regulation of cell
differentiation
Tollip 2
Pgf 2 Tiam1 4 Kdr 5 Oasl1 2 F5 2
Hmox1 2 Axl 2 Thbd 4 Plaur 2 F3 2
Epha2 2 Epha2 2 Egf like Cfi 2 Tiam1 4 Tnfrsf1b 2
Ctnnb1 2 Arid5b 3 Ltbp1 2 B2m 4 Igfbp3 6 Pf4 2
Cav1 3 Ctgf 3 Lamb1-1 3 Cxcl12 4 Id2 3 Cxcl1 4
Ctgf 3 Vegfa 6 Epha2 2 Thbd 4 Tnfrsf12a 4 Tgfbr2 2
Gna13 2 Nrp1 2 Hyal2 3 Bnip3 4 Cd74 3 Myd88 2
Trp63 3 Eng 3 Lama2 3 Negative regulation of
apoptosis
Inpp5d 4 Fntb 3
Hes1 2 Skil 2 Vcan 2 Ets1 5 Nfkbiz 4
Adamts1 5 Egf 2 Plau 3 Btg1 4 Tlr4 2
Tnfrsf12a 4 Pdgfra 5 Thbs2 4 Angptl4 6 H2-aa 4 Loc640441 3
Vegfa 6 Tgfbr3 3 Itgb1 2 Bcl2l1 3 Foxo3 3 Plaur 2
Nrp1 2 Flt1 6 Lamc2 2 Btg2 3 Junb 3 Gja1 3
Eng 3 Eif4ebp1 2 Pamr1 3 Bnip3l 2 Socs3 5 Cfi 2
Dll4 2 Adam9 2 Dll4 2 Myc 5 Brlz Sphk1 3
Egf 2 Tgfbr2 2 Cd93 3 Trp63 3 Mafk 3 Thbd 4
Cyr61 3 Myd88 2 Egf 2 Cdkn1a 4 Bach1 3 Sex dev.
Nr4a3 2 Csrnp1 4 Pear1 4 Vegfa 6 Atf3 4 Acvrl1 5
Nos3 3 Tiparp 3 Tnc 2 Pim1 3 Fosl2 3 Lamb1-1 3
Pdgfra 5 Smad6 2 Mfge8 3 Cd74 3 Maff 5 Pafah1b2 3
Tgfbr3 3 Plekha1 2 Adam9 2 Snca 2 Junb 3 Ctnnb1 2
Flt1 6 Ltbp4 2 Eltd1 4 Csda 2 Cebpb 5 Cav1 3
Mgp 2 Pik3r1 3 Loc640441 3 Bag3 2 Cebpd 6 Bcl2l1 3
Mfge8 3 Foxo1 5 Ltbp4 2 Tsc22d3 4 Mafb 3 Sirt1 3
Adm 3 Kdr 5 Clec14a 3 Agt 2 C2h2 like Spata9 3
Col4a1 5 Receptors Ptgs1 2 Gclc 2 Rnf166 3 Dab2 6
Col4a2 5 Acvrl1 5 Thbd 4 Cited2 3 Zkscan17 3 Trp63 3
Cdh5 3 Axl 2 Heg1 2 Pik3r1 3 2810021j22rik 2 Adamts1 5
Agt 2 Cd36 2 Growth factor
binding
Foxo1 5 Hinfp 5 Vegfa 6
Robo4 3 Gab2 2 Cebpb 5 Zfp661 4 Sf1 3
Tgfbr2 2 Pgrmc1 3 Sphk1 3 Zfp39 3 Itgb1 2
Tiparp 3 Epha2 2 Ltbp1 2 Bnip3 4 Zfp750 2 Xrn2 3
Twist1 2 Hyal2 3 Htra1 3 Prnp 3 Zfp691 3 Ccna1 2
Btg1 4 Mertk 2 Igfbp4 2 Negative regulation of cell
differentiation
Gm6766 4 Cyr61 3
Adamts2 2 Scara5 2 Ctgf 3 Zfp512 2 Tnc 2
Loc100046643 4 Ednrb 2 Igfbp3 6 Krab Nos3 3
Cited2 3 Osmr 3 Eng 3 Ctnnb1 2 Zkscan17 3 Pdgfra 5
Loc640441 3 Ppara 3 Cyr61 3 Cav1 3 2810021j22rik 2 Tgfbr3 3
Zc3h12a 2 Il15ra 3 Pdgfra 5 Sirt1 3 Zfp661 4 Csda 2
Foxo1 5 Tnfrsf12a 4 Tgfbr3 3 Nfkbia 4 Zfp39 3 Tead4 3
Shb 4 Itgb1 2 Col4a1 5 Trp63 3 Pogk 4 Adm 3
S1pr1 2 Nrp1 2 Ltbp4 2 Hes1 2 Btb / btb poz Sfrp1 2
Gja1 3 Fcgr2b 3 Kdr 5 Rcan1 4 Kctd2 2 Agt 2
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Table 1 Spalax hypoxia induced genes belonging to selected enriched terms (Continued)
Junb 3 Mrc1 2 Immune Response Cd74 3 Zbtb4 3 Egln1 3
Socs3 5 Slc20a1 2 Vwf 2 Itgb1 2 Rhobtb1 2 Cadm1 2
Rhob 4 Cd93 3 Gadd45g 4 Nrp1 2 Btbd11 2 Klf9 4
Cxcl12 4 Trpc4 2 Cxcl14 3 Inpp5d 4 Rhobtb2 2 Adamts2 2
Sphk1 3 Ptgfrn 4 Plau 3 Skil 2 Loc100046682 3 Siah1a 4
Kdr 5 Nr4a3 2 Bnip3l 2 Wwtr1 6 Ipp 2 Slc30a1 5
Ecm receptor
interaction
Tnfrsf1b 2 Serping1 2 Tgfbr3 3 Klhl8 2 Cited2 3
Errfi1 5 Vegfa 6 Pf4 2 Kbtbd8 2 Serpina5 4
Pdgfra 5 Cd74 3 Rnf6 2 Klhdc5 3 Maff 5
Vwf 2 Tgfbr3 3 Tollip 2 Twist1 2 Zbtb38 2 Nrip1 2
Lamb1-1 3 Flt1 6 Inpp5d 4 Pik3r1 3 Kctd21 4 Foxo3 3
Cd36 2 Robo4 3 F5 2 Zfp36 2 Gm6766 4 Aff4 2
Sdc4 2 Tgfbr2 2 Fcgr2b 3 Zbtb16 5 Gm14457 3 Gja1 3
Lama2 3 Lpar1 2 F3 2 Cav1 3 Zbtb12 2 Junb 3
Thbs2 4 Tlr4 2 Tnfrsf1b 2 Igfbp3 6 Spop 2 Socs3 5
Itgb1 2 Eltd1 4 Tinagl1 4 Cdkn1a 4 Loc638050 2 Kdm3a 3
Col5a2 2 Pnrc1 3 Pf4 2 Sf1 3 Wounding Cebpb 5
Lamc2 2 C3ar1 2 Cxcl1 4 Inpp5d 4 Klf6 4 Cxcl12 4
Tnc 2 Chrnb1 2 Cadm1 2 Fcgr2b 3 Vwf 2 Ppp1r1b 2
Col4a1 5 Cmklr1 3 Myd88 2 Nos3 3 Entpd2 2 Kdr 5
Col4a2 5 Gm5898 2 Sbno2 2 Tgfbr3 3 Igfbp4 2 Zbtb16 5
Loc640441 3 Cxcr7 5 H2-aa 4 Cdh5 3 Map2k3 4 Thbd 4
The number of conditions in which significant over/underexpression was detected in the microarray is shown to the right of the gene symbol, for 215 different
genes. The list is based on Additional file 3: Tables S3 and Additional file 4: Table S4 for genes with unambiguous annotations. Group titles in bold, represent
specific functional terms or groups of synonymous terms. Sex dev. Denotes reproductive development. Enzyme linked receptor denotes enzyme linked receptor
signaling pathway. Brlz denotes basic leucine zipper TF.
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the non-responsive probe), and high fold change differ-
ences (>2 or <0.5) (Table 2 and Additional file 7: Table
S7). These 66 genes include different tumor or angiogen-
esis suppressors such as Rcan1 (upregulated by >10 fold
in Spalax mu6), and apoptotic genes such as G0s2
(downregulated by 25 fold in Spalax mu6). G0s2 is a
pro-apoptotic gene, and its observed downregulation
may contribute to cell survival under hypoxia in Spalax.
It is possible that some of the above differences reflect
variation in probe sensitivity between rat and Spalax
microarrays, but we still expect that strong differences
have true biological repercussions in most cases.
Validation of microarray expression results
Real time quantitative PCR was conducted on two groups
of genes of interest in order to validate the microarray
results. Two genes with known functions that repress
angiogenesis, Regulator of Calcineurin (Rcan1) also known
as Down Syndrome Critical Region 1 (Dscr1), and Throm-
bospondin (Tsp1), both highly upregulated in Spalax
muscle at 6% O2 with no response in rat, were tested
using the same samples as used for the microarray experi-
ments together with addition biological replicates. Rcan1
expression was induced by 6-fold, 13-fold and 2-foldunder conditions of 3%, 6%, and 10% O2, respectively.
Tsp1 was induced by 17-fold, 19-fold, and 2-fold under
the same conditions (Figure 9). Samples from a second
species of Spalax (S. judaei) exposed to identical condi-
tions were also tested for these genes by RLT-q-PCR with
no significant changes between normoxic and hypoxic
conditions (data not shown).
The second group of genes tested by RLT-q-PCR was
chosen from the contractile and muscle fiber ontology
groups. Three genes from the troponin gene family,
which among other related genes showed extremely high
induction uniquely in Spalax brain under 10% O2, were
tested in order to confirm results. Results for Troponin
C2 (Tnnc2), Troponin I2 (Tnni2) and Troponin T3
(Tnnc3) show increased expression of 17, 35, and
25-fold, respectively, under 10% O2 (Figure 9). Again, S.
judaei was tested for these genes under similar condi-
tions, however no significant changes were observed
when comparing normoxic to hypoxic conditions. We
also tested the Troponin genes in Spalax muscle tissue.
While basal normoxic levels of Tnnc2, Tnni2 and Tnnc3
were 548, 2005, and 1200-fold higher in muscle than in
brain, no response to hypoxia was observed in muscle
tissue. S. galili is known to have higher hypoxia toler-
ance compared with S. judaei, due to differences of
Figure 5 Functional groups significantly enriched among genes downregulated in Spalax under hypoxia. Bars represent gene counts for
the different gene ontology terms.
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http://www.biomedcentral.com/1471-2164/13/615climatic regimes in their ranges of distribution. Environ-
mental hypoxia climaxes during winter rains and flood-
ing, when gas solubility and permeability are restricted,
and is highest in Spalax species living under humid cli-
mates (e.g., S. galili), compared with those living in more
arid conditions (e.g., S. judaei). Spalax expression stud-
ies have previously demonstrated significant differences
between the two species in response to hypoxia [9].
Discussion
Here we show that different functional groups of genes
are significantly overrepresented during hypoxia stress in
Spalax. We suggest that these nonrandom patterns re-
flect the activation of specific physiological and molecu-
lar processes which contribute to hypoxia tolerance. We
discuss how such processes, as well as individual genes,
may contribute to hypoxia tolerance in Spalax.
Crosstalk between angiogenesis, immune response, and
apoptotic control, in Spalax hypoxia
Processes directly involved in the formation of vascular
morphology, such as angiogenesis, vasculature develop-
ment, and Vegf signaling, were significantly enriched
among hypoxia activated genes in most conditions (i.e.,
br3, br6, br10, mu3, mu6). In addition, we find that hyp-
oxia activated Spalax genes are significantly enriched with
a battery of ontologies that are known to be associated
with angiogenesis including extracellular matrix (ECM),
cell-cell/cell-ECM adhesion, focal adhesion, pattern bind-
ing, immune response, inflammatory response, woundhealing, receptor tyrosine kinase activity, among others
(see Figures 3, 4, 5, 6, 7 and 8). The ECM is known to en-
code chemotactic, haptotactic, and mechanotactic cues,
that are crucial for the control of endothelial cell (EC) mi-
gration, and their interaction with supporting cells [29,30].
During angiogenesis the ECM also modulates EC cell sur-
vival by integration of signals induced by the binding of
EC integrins to the ECM, with those induced by growth
factors [30]. Multiple factors affect cell survival, including
hypoxia and inflammation, which are known to modulate
the balance between EC apoptosis and survival. Our
results indicate that in addition to the expected apoptotic
response, strong regulation of anti-apoptotic genes is
observed in Spalax during hypoxia.For example, we find
that the Foxo3a gene, which critically inhibits HIF1a
induced apoptosis in mouse [31] is upregulated in mu3/6/
10. Moreover, most of the well studied key genes in the
Foxo3a cell survival pathway are differentially expressed in
Spalax muscle, namely: Pi3k, Pkb (Akt1), mTOR, Foxo3a,
Cited2, Nix (Bnip3L), and RTP801 (Figure 10). This may
reflect a fine balance between inducers and suppressors of
apopototic pathways. Accordingly, it appears that hypoxia
induced apoptosis is tightly controlled, and possibly
restricted in Spalax. Similarly, previous studies suggested
that critical p53 hypoxia induced apoptotic pathways are
blocked in Spalax [15,16]. Also, the accepted functions
assigned to genes among the common databases may not
reflect the true functions of homologues in all organisms,
for example, the p53 pathway as mentioned above. It was








































































positive regulation of gene expression
protein dimerization activity
regulation of apoptosis
transmembrane receptor protein tyrosine kinase signaling pathway











development of primary sexual characteristics
signal
embryonic organ development
regulation of cell proliferation
basement membrane
Basic-leucine zipper (bZIP) transcription factor / BRLZ 
negative regulation of apoptosis
reproductive developmental process
Extracellular




positive regulation of immune system process
programmed cell death









br6  gene count
Figure 6 Functional groups significantly enriched among genes upregulated in Spalax brain under acute hypoxia (br3, br6). Series
names: brain upregulation in hypoxia for 3% 6 hrs, and 6% 6 hrs, are denoted br3 (blue), br6 (red), respectively. Line chart (triangles, diamonds)
represents Benjamini adjusted P-value of term enrichment. Bars denote gene counts.
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http://www.biomedcentral.com/1471-2164/13/615tolerance evolution require a common shift toward antia-
poptotic functions. This hypothesis can be supported by
different experimental results, suggesting that non-
pathological internal hypoxia may be frequent during Spa-
lax life. In contrast, in most adult mammals, the occur-
rence of internal hypoxia more frequently reflects
unwanted cellular abnormalities.
Strong elevation of key antiangiogenic genes in Spalax
under hypoxia
The process of angiogenesis or the sprouting of new
blood vessels from existing ones is controlled by a bal-
ance of pro and antiangiogenic factors [33]. Among
these factors Vegf is probably the most studied, and ele-
vated levels of this gene product were shown to play a
critical role in the inherently dense vasculature of Spalax
muscle. Unlike the rat and other mammals, Spalax Vegfremains at constant levels in muscle under hypoxic con-
ditions and even downregulated under certain hypoxic
stresses [6,17]. Our microarray data shows Spalax Vegf
downregulation in muscle and upregulation in brain
under hypoxic conditions. However, in response to hyp-
oxia, a number of genes with known antiangiogenic
function are highly expressed in Spalax muscle. Throm-
bospondin 1 (Tsp1), upregulated by a factor of 19-fold in
Spalax hypoxic muscle, was one of the first genes to be
recognized as a suppressor of angiogenesis [34,35] and
works through a number of mechanisms including sup-
pression of the bioavailability of Vegf and inhibition of
endothelial cell migration [36]. Down Syndrome Critical
Region 1 (Dscr1 also known as Rcan1), a negative regula-
tor of calcineurin and suppressor of angiogenesis lies in
the region of human chromosome 21, which in the triso-
mic state is implicated as the major cause of Down’s
Figure 7 Functional groups significantly enriched among genes upregulated in Spalax muscle under acute and chronic hypoxia (mu3,
mu6, mu10). Series names: muscle upregulation at 3% 6 hrs, 6% 6 hrs, 10% 44 hrs hypoxia, are denoted mu3 (blue), mu6 (red), mu10 (green),
respectively. Line chart (triangles, diamonds, and circles) represents Benjamini adjusted P-value of term enrichment. Bars denote gene counts.
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http://www.biomedcentral.com/1471-2164/13/615Syndrome. Individuals with Down’s Syndrome have a
much lower incidence of solid tumors than the general
population and this is attributed to the inherently higherlevels of Dscr1 and suppresion of angiogenesis, thus the
inability of tumors to develop under hypoxic conditions.
In a mouse model, it was demonstrated that a single extra
Figure 8 Functional groups significantly enriched among genes upregulated in Spalax brain after 10% 44hrs hypoxia (br10). Red line
chart (scale on the top) shows Benjamini adjusted P-value for specific ontology terms. Blue bar (bottom scale) denotes gene counts. The listed
terms were first clustered, so that similar categories are typically adjacent.
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to reduced tumor angiogenesis [37]. In our experiment we
observed a 13-fold induction of Dscr1 in hypoxic Spalax
muscle under 6% hypoxia. Induction of these genes may
confer the tight control of Vegf and angiogenic stability
under hypoxic conditions in Spalax. Both of these genes
have been proposed as potential targets for cancer therapy
[38]. Recently we have proposed Spalax as a model organ-
ism for both hypoxia tolerance and cancer resistance, as wehave never seen the spontaneous development of solid
tumors in these animals, including many that have been in
captivity for over 20 years. These genes may also play a crit-
ical role in cancer suppression in Spalax.
Protective processes in Spalax brain under
chronic hypoxia
Numerous findings indicate that the properties of the
blood brain barrier (BBB) and its constituents are
Table 2 Differences in hypoxia induced expression between Spalax and rat genes
Fold/Fold Tissue Symbol Rat Gene p.adj Fold i p.adj Fold i
spalax/rat 4.1 mu6 Cd44 ENSRNOG00000006094 1.3E-03 3.8 626 9.3E-01 0.9 227
spalax/rat 2.9 mu6 Htra1 ENSRNOG00000020533 1.9E-04 3.5 865 5.3E-01 1.2 433
spalax/rat 3.0 mu6 Myc ENSRNOG00000004500 9.6E-06 5.1 319 6.4E-01 1.7 303
spalax/rat 2.8 mu6 Dirc2 ENSRNOG00000002240 9.9E-04 2.3 627 7.3E-01 0.8 939
spalax/rat 9.2 mu6 Rcan1 ENSRNOG00000001979 9.3E-05 11.5 4651 7.4E-01 1.3 1362
spalax/rat 3.6 mu6 Cdkn1a ENSRNOG00000000521 9.8E-04 4.1 534 5.9E-01 1.2 6085
spalax/rat 2.5 mu6 Synj2 ENSRNOG00000017114 5.6E-05 3.2 376 6.8E-01 1.3 1070
spalax/rat 22.5 mu6 Tnfrsf12a ENSRNOG00000003546 3.1E-05 13.8 3805 6.7E-01 0.6 479
spalax/rat 5.5 mu6 Uimc1 ENSRNOG00000016891 2.4E-03 6.3 27190 8.9E-01 1.1 494
spalax/rat 2.0 mu6 Mall ENSRNOG00000015599 1.4E-02 2.3 524 7.4E-01 1.2 295
spalax/rat 2.8 mu6 Fuca1 ENSRNOG00000009325 5.3E-03 2.4 961 9.9E-01 0.9 1251
spalax/rat 5.7 mu6 Csrp3 ENSRNOG00000014327 2.9E-04 4.2 146 5.2E-01 0.7 6760
spalax/rat 4.5 mu6 Tyrobp ENSRNOG00000020845 2.0E-03 3.6 1382 6.5E-01 0.8 395
spalax/rat 2.9 mu6 Bag3 ENSRNOG00000020298 9.8E-04 3.6 21589 9.1E-01 1.2 4629
spalax/rat 5.9 mu6 Pank1 ENSRNOG00000018944 4.0E-04 4.4 451 5.2E-01 0.7 329
spalax/rat 2.2 mu6 Btg1 ENSRNOG00000004284 2.1E-04 2.1 1075 9.2E-01 0.9 1426
spalax/rat 2.7 mu6 Rbm24 ENSRNOG00000016925 4.1E-04 2.5 4026 1.0E+00 0.9 201
spalax/rat 3.9 mu6 Mical2 ENSRNOG00000016244 1.1E-02 3.6 263 9.9E-01 0.9 200
spalax/rat 3.5 mu6 Cpeb2 ENSRNOG00000005043 2.2E-04 2.6 315 6.9E-01 0.7 959
spalax/rat 3.7 mu6 Cited2 ENSRNOG00000012193 2.9E-05 7.5 2023 8.5E-01 2.0 334
spalax/rat 4.9 mu6 Hspb8 ENSRNOG00000022392 3.2E-04 3.3 31123 5.8E-01 0.7 771
spalax/rat 6.7 mu6 Abra ENSRNOG00000007999 1.3E-03 5.1 25220 6.6E-01 0.8 5289
spalax/rat 3.2 mu6 Cxcr7 ENSRNOG00000019622 2.6E-03 4.4 1227 5.0E-01 1.4 321
spalax/rat 3.6 mu6 Lrrc30 ENSRNOG00000030389 9.1E-06 4.0 3162 9.9E-01 1.1 406
spalax/rat 2.3 mu6 Prnp ENSRNOG00000021259 4.0E-04 2.4 904 9.7E-01 1.0 1019
spalax/rat 7.7 mu6 Neu2 ENSRNOG00000016962 8.4E-04 4.0 145 7.0E-01 0.5 816
spalax/rat 2.8 br6 Hyal2 ENSRNOG00000031420 5.5E-04 2.9 1212 1.0E+00 1.0 1895
spalax/rat 2.4 br6 Igfbp3 ENSRNOG00000008645 4.2E-04 2.5 254 9.5E-01 1.0 696
spalax/rat 13.6 br6 Glt8d1 ENSRNOG00000018179 4.2E-04 11.7 497 7.6E-01 0.9 485
spalax/rat 2.7 br6 Kcnc2 ENSRNOG00000004077 2.5E-02 3.1 129 7.8E-01 1.1 1518
spalax/rat 3.9 br6 Junb ENSRNOG00000042838 6.2E-04 2.5 2276 6.7E-01 0.6 4618
spalax/rat 0.02 mu6 G0s2 ENSRNOG00000006019 6.5E-05 0.04 3960 8.7E-01 1.6 11657
spalax/rat 0.2 mu6 Rgs2 ENSRNOG00000003687 7.0E-03 0.3 627 6.7E-01 1.7 618
spalax/rat 0.3 mu6 Akr1e1 ENSRNOG00000017165 4.8E-03 0.2 552 8.7E-01 0.8 765
spalax/rat 0.3 br6 Cnksr3 ENSRNOG00000018052 5.0E-02 0.4 1561 8.6E-01 1.3 209
spalax/rat 0.5 br6 Dek ENSRNOG00000016152 2.1E-02 0.4 2266 7.7E-01 0.9 2232
spalax/rat 0.4 br6 Dhrs4 ENSRNOG00000018239 1.6E-02 0.5 6739 8.0E-01 1.1 253
spalax/rat 0.5 br6 Golga4 ENSRNOG00000029910 7.7E-03 0.5 4883 9.8E-01 1.0 4198
rat/spalax 2.0 mu6 D930049a15rik ENSRNOG00000010488 7.5E-01 1.1 336 3.7E-03 2.3 221
rat/spalax 18.1 mu6 Ccng1 ENSRNOG00000003256 9.8E-01 1.0 13045 3.0E-02 18.0 6981
rat/spalax 3.5 mu6 Lman2 ENSRNOG00000016161 9.3E-01 1.0 262 5.5E-03 3.5 5729
rat/spalax 2.8 mu6 Tfrc ENSRNOG00000001766 7.6E-01 0.8 2688 2.5E-02 2.1 107
rat/spalax 4.2 mu6 Slc25a25 ENSRNOG00000014338 9.9E-01 1.2 2496 2.4E-02 5.0 6771
rat/spalax 3.4 mu6 Pde4b ENSRNOG00000005905 6.9E-01 1.1 479 1.2E-02 3.8 248
rat/spalax 2.2 mu6 Iqcg ENSRNOG00000026420 7.5E-01 1.2 640 3.7E-02 2.7 159
rat/spalax 4.1 mu6 Loc100045963 ENSRNOG00000009028 7.9E-01 1.0 359 1.0E-02 4.0 3102
rat/spalax 4.6 mu6 Myf6 ENSRNOG00000004878 7.7E-01 0.7 1077 3.0E-02 3.3 3508
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Table 2 Differences in hypoxia induced expression between Spalax and rat genes (Continued)
rat/spalax 4.5 mu6 Txnip ENSRNOG00000021201 7.9E-01 1.1 12024 6.8E-03 4.9 6996
rat/spalax 3.3 mu6 D0h4s114 ENSRNOG00000020467 8.3E-01 0.9 1720 4.8E-02 3.0 699
rat/spalax 5.8 mu6 Junb ENSRNOG00000042838 5.5E-01 1.5 1300 8.5E-04 8.7 3795
rat/spalax 2.5 br6 Pla1a ENSRNOG00000027252 5.8E-01 1.1 448 2.5E-03 2.7 372
rat/spalax 2.2 br6 Cnp ENSRNOG00000017496 7.7E-01 1.0 13280 1.5E-02 2.3 1677
rat/spalax 2.8 br6 Fn1 ENSRNOG00000014288 9.8E-01 0.9 937 1.9E-03 2.6 1577
rat/spalax 2.6 br6 Mfsd2a ENSRNOG00000014008 9.1E-01 0.9 738 5.5E-04 2.4 703
rat/spalax 3.5 br6 Alas1 ENSRNOG00000000167 8.9E-01 1.0 2449 2.1E-03 3.6 1689
rat/spalax 0.4 mu6 Znf512b ENSRNOG00000015558 6.8E-01 0.9 259 5.2E-03 0.4 1730
rat/spalax 0.4 mu6 Ier3 ENSRNOG00000000827 7.5E-01 1.1 1509 8.2E-03 0.4 281
rat/spalax 0.5 mu6 Ezh1 ENSRNOG00000020336 9.7E-01 1.1 1965 4.0E-02 0.5 2366
rat/spalax 0.4 mu6 Dynll1 ENSRNOG00000011222 5.1E-01 0.9 22039 1.9E-02 0.4 2236
rat/spalax 0.4 mu6 Rpap1 ENSRNOG00000005483 5.1E-01 1.1 575 2.6E-03 0.4 249
rat/spalax 0.4 mu6 Ypel3 ENSRNOG00000019721 8.4E-01 1.0 2745 6.0E-03 0.4 769
rat/spalax 0.5 mu6 Sat2 ENSRNOG00000011714 7.4E-01 1.0 205 1.6E-03 0.5 209
(p.adj) denotes adjusted p-value for hypoxia differential expression, (i) denotes probe intensity, Fold denotes fold change, where columns with italics title refer to
Spalax and columns with plain titles refer to rat.
Malik et al. BMC Genomics 2012, 13:615 Page 15 of 20
http://www.biomedcentral.com/1471-2164/13/615modulated during hypoxia and angiogenesis [30,39,40].
High altitude cerebral edema, a severe form of altitude
sickness characterized by brain tissue swelling, is caused
by hypoxia induced disturbance in the BBB, e.g., increased
BBB permeability. Normally, the BBB maintains an ionic/
molecular/volume homeostasis of brain interstitial fluids
and, therefore, stabilizes synaptic/axonal signaling and
blocks excessive crosstalk between different CNS compart-
ments [40]. Among Spalax br10 genes, processes known
to disturb BBB functions, such as inflammation, angiogen-
esis, and Vegfr signaling, are significantly overrepresented
(Figure 8). Therefore, it is probable that Spalax developed
opposing mechanisms that balance between BBB selectiv-
ity and hypoxia induced BBB permeability, which together
promote brain homeostasis under hypoxia. We speculate
that the observed enrichment of contractile fiber genes in
br10 (Figure 8) may reflect hypoxia induced changes in the
neurovascular unit cells in the BBB. Specifically, this pat-
tern may reflect increased numbers and activities of peri-
cytes and smooth muscle cells, which are known to
express contractile fiber genes. Accordingly, hypoxia
induced pericyte contraction was found to be critical in
pathological processes in mouse brain [41]. The ‘contract-
ile fiber’ group includes two upregulated genes that encode
the known pericyte markers Abcc9, and Kcnj8 [42]. In
addition, it was found that pericytes express tropomyosins
[43], of which, Tpm2 and Tpm4 were detected in the
group of upregulated genes, and were mapped to the term
‘muscle protein’. This furthur supports the evidence of
angiogenic processes with corresponding pericyte activity.
Collectively, it appears that chronic mild hypoxia in Spalax
brain induces very strong angiogenic responses in Spalax,
and it remains to be seen how blood brain barrier homeo-
stasis is maintained under these conditions.Alternate groups of TFs are expressed during hypoxia,
in Spalax
It appears that hypoxia coordinates a transcriptional
switch, in which distinct groups of TFs transcripts are
suppressed, while others are increased, in Spalax. Ac-
cordingly, genes involved in the regulation of transcrip-
tion were significantly overrepresented among both
downregulated and upregulated genes, especially in brain
and muscle tissues under acute hypoxia. In addition,
under these conditions, bZIP TFs were found to be over-
represented, whereas C2H2 Zinc-finger TFs were found
to be underrepresented. The family of bZIP TFs is char-
acterized by a highly conserved basic region (BR), and a
leucine zipper (LZ) domain that allows homo- and
hetero-dimerization of bZIP monomers [44,45]. The
DNA binding affinity of bZIP dimers (which constitutes
the active TFs), is known to be regulated either by redox,
or by phosphorylation, possibly depending on specific
cystein/serine residues at position 19 of the highly con-
served BR [44]. The activation of bZIPs via redox
mechanisms was suggested to depend on oxidative
stress, one of the major characteristics of hypoxia.
Therefore, it is possible that this group of Spalax bZIPs
is activated by oxidative stress during severe 3% hypoxia.
As noted above, the upregulation of bZIP transcripts is
accompanied by a decrease of C2H2-like zinc finger
transcripts. In addition, a small group of C2H2-like zinc
finger genes, belonging to the KRAB zinc finger family,
is overrepresented among downregulated genes in br3
and mu3 (Figure 5). While we did not specifically ob-
serve activation or deactivation of these trancription fac-
tors, transcript levels of the different groups were
increased or reduced under hypoxic conditions. KRAB
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Figure 9 Hypoxia induced differential expression results for antiangiogenic and contractile fiber genes, based on RT-Q-PCR. Left: fold
change (hypoxia/normoxia) for Dscr1 and Tsp1antiangiogenic genes, under 3%/6%/10% hypoxia in muscle 6%. Right: fold change for Tnnc2, Tnni2,
and Tnnt3contractile genes, under 10% hypoxia in the brain.
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http://www.biomedcentral.com/1471-2164/13/615suppression of transcription, as part of KAP1 mediated
targeting of heterochromatin protein 1 (HP1) to DNA
[46]. It was suggested that this mechanism allows KRAB
zinc finger TFs to ‘auto-regulate’ other zinc finger TFs
[47]. It is therefore possible that the observed reduction
of KRAB TF transcript levels in hypoxia reflects the in-
volvement of processes related to epigenetic control,
which may lead to long term effects (e.g., after the return
to normoxia). Due to these and other long-term effects,
epigenetic modifications may potentially facilitate hyp-
oxia preconditioning and postconditioning, which has
therapeutic importance in limiting ischemia/reperfusion
damage [48,49].Overlap between hypoxia and cancer induced genes in
Spalax muscle
The present results corroborate with the known interre-
lations between hypoxia and cancer conditions [18].
Hypoxia responsive genes in Spalax muscle are signifi-
cantly enriched with cancer related genes. In mu10, the
enriched term ‘pathways in cancer’ is mapped to several
known genes of special importance, such as Vegf,Vegfr2,
Glut1, Egf, Fdgr, Pi3k, Fak, Foxo1, p21, and Myc. Simi-
larly, in mu3, and mu6, a group of proto-oncogenes is
significantly enriched. In addition, key genes participat-
ing in glucose uptake and the lactate clearance pathway
during cancer are found to be upregulated in both br3
and br6 (Figure 10) [50,51]. It is possible that lactate
clearance has an anti-apoptotic role, as this mechanism
reduces acidosis, a condition which may trigger apop-
tosis. Lactate transported out of hypoxic cells may be
recycled by neighboring normoxic cells as part of angio-
genesis, in both normal and cancer conditions [32]. It
also appears that a group of mitochondrial genes, which
includes different oxidative phosphorylation genes, is
enriched among hypoxia suppressed Spalax genes.Developmental genes during hypoxia, in Spalax
In the present study, genes associated with different
developmental processes were significantly overrepre-
sented under hypoxia. Corresponding ontology terms
include reproductive development, sexual reproduc-
tion, embryonic development, skeletal system develop-
ment, face morphogenesis, wound healing, as well as
angiogenesis related processes. In general, normal de-
velopmental processes are known to be tightly con-
trolled by spatiotemporal hypoxia gradients [52]. In
embryonic development, hypoxia gradients serve as
essential signals that trigger a Hif dependent shift be-
tween different developmental stages, thereby modu-
lating differentiation, proliferation, apoptosis, and
vascularization. For example, Labyrinthine layer devel-
opment, which is a process known to be specifically
coordinated by hypoxia in the placenta is overrepre-
sented among br3\mu3 activated genes [52]. In
addition, Egf like growth factors, which are overrepre-
sented among mu3 and br10 responsive genes, may
also be involved in developmental processes [53].
These growth factors were suggested to serve as po-
tent insoluble ECM-bound Egfr-receptor ligands [54]
and promote mitogenic activity, though their func-
tions are diverse. Altogether, it is possible that the
observed overrepresentation of development related
genes reflects the control of cell proliferation vs. dif-
ferentiation, during hypoxia in Spalax.Glycoproteins and disulfide-bond forming proteins during
hypoxia in Spalax
Genes encoding membrane/transmembrane/secreted
proteins, glycoproteins, disulfide-bond forming pro-
teins, and signal peptide containing proteins, are found
to be highly overrepresented under most hypoxic con-
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disulfide-bonds are usually found in transmembrane
domains, or in proteins secreted to extracellular envir-
onments [55]. The observed large overlap, between the
ontologies disulfide-bond, and signal peptide, mainly
reflects the role signal peptide domains play in the
post-translational transport of disulfide-bond contain-
ing proteins to the rough endoplasmic reticulum, as
part of their normal processing. Accordingly, very large
groups of hypoxia induced genes are involved in medi-
ating cellular interaction with the extracellular environ-
ment, which may point toward their involvement inangiogenesis, immune response, and signal transduc-
tion. As pointed out previously [21], the overrepresen-
tation of disulfide bond forming proteins may partly
reflect oxygen dependent mechanisms, as these bonds
are formed by the oxidation of the thiol groups in
cysteins, and are dissociated when the cellular oxygen
pressure is diminished thereby leading to changes in
protein conformation and activity [56,57]. It was sug-
gested that proper folding of disulfide bond containing
proteins (e.g., Vegf ) is compromised under hypoxia,
and that specific Hif dependent pathways increase cor-
rect protein folding and secretion [58].
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(1) The present study identifies multiple hypoxia
induced gene and pathway responses in Spalax.
Expression patterns of these genes reflect
mechanisms of hypoxia tolerance that enhance
survival in a high stress environment, with both
special evolutionary and biomedical importance.
Previous studies have demonstrated multiple
differences between Spalax and rat expression
patterns under hypoxia, thus, it is expected that
many of the patterns observed here may be unique
to Spalax.
(2) Expression patterns of apoptosis and angiogenesis
related genes confirms previous research suggesting
suppression of apoptosis for enhanced survival and
the tight regulation of angiogenic factors similar to
studies of cancer cells.
(3) Histological detection of proteins coded by Spalax
hypoxia induced genes can help understand the
physiological context under which hypoxia related
processes act. Such tests will be specifically useful
for studying transcripts mapped to enriched
ontologies.
(4) The enrichment of C2H2 zinc-finger TFs, KRAB
TFs, mitochondrial and ribosomal genes, among
hypoxia suppressed genes, may reflect critical
responses to hypoxia. As genes belonging to these
groups tend to have different paralogs, better
understanding of the results will require mapping
contigs and microarray probes to the Spalax
genome when it becomes available.
(5) The identification of specific genes that are highly
regulated and may be critical to Spalax survival
under conditions of stress serve as an example of
the critical need to study the evolution of organisms
in a wide range of diverse habitats as part of the
search for candidate targets for treatment of human
pathologies.Additional files
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